• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion.比较有和没有阴道下三分之一受累的IIIB期宫颈癌患者的治疗结果。
J Gynecol Oncol. 2017 Nov;28(6):e79. doi: 10.3802/jgo.2017.28.e79.
2
Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.根治性子宫切除术及辅助放疗或放化疗治疗宫颈腺癌或腺鳞癌的临床行为和结局。
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):420-7. doi: 10.1016/j.ijrobp.2011.12.013. Epub 2012 Feb 24.
3
Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.在妇科肿瘤学组基于顺铂的同步放化疗试验中,宫颈局部晚期腺癌和腺鳞癌与宫颈鳞状细胞癌的比较
Gynecol Oncol. 2014 Nov;135(2):208-12. doi: 10.1016/j.ygyno.2014.08.018. Epub 2014 Aug 23.
4
Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.对于FIGO IIIB/IVA期宫颈癌患者,采用化疗放疗后序贯含紫杉醇和卡铂的巩固化疗。
J Gynecol Oncol. 2017 Jan;28(1):e15. doi: 10.3802/jgo.2017.28.e15.
5
Neoadjuvant weekly carboplatin and paclitaxel followed by radical hysterectomy for locally advanced cervical cancer: long-term results.新辅助每周卡铂和紫杉醇联合根治性子宫切除术治疗局部晚期宫颈癌:长期结果。
Int J Gynecol Cancer. 2010 May;20(4):611-6. doi: 10.1111/IGC.0b013e3181d80aa9.
6
Treatment outcomes of locally advanced cervical cancer by histopathological types in a single institution: A propensity score matching study.单中心研究:不同组织学类型局部晚期宫颈癌的治疗结局:倾向评分匹配研究。
J Formos Med Assoc. 2018 Oct;117(10):922-931. doi: 10.1016/j.jfma.2018.07.002. Epub 2018 Jul 17.
7
Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.伴有危险因素的ⅠB - ⅡB期宫颈腺癌根治术后的辅助治疗。
Jpn J Clin Oncol. 2017 Jan;47(1):32-38. doi: 10.1093/jjco/hyw145. Epub 2016 Sep 27.
8
[Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma].[同步放化疗与单纯放疗治疗晚期宫颈癌的比较]
Ai Zheng. 2008 Sep;27(9):942-6.
9
Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors.局部晚期宫颈癌同期放化疗联合高剂量率近距离放疗:生存结果、失败模式和预后因素。
Int J Gynecol Cancer. 2010 Apr;20(3):428-33. doi: 10.1111/IGC.0b013e3181d4a0d1.
10
Comparison of the survival outcome of neoadjuvant therapy followed by radical surgery with that of concomitant chemoradiotherapy in patients with stage IB2-IIIB cervical adenocarcinoma.比较新辅助治疗后根治性手术与同期放化疗治疗 IB2 期至 IIIB 期宫颈腺癌患者的生存结局。
Arch Gynecol Obstet. 2021 Mar;303(3):793-801. doi: 10.1007/s00404-020-05826-6. Epub 2020 Oct 3.

引用本文的文献

1
Cervical cancer: Challenges and prevention strategies: A narrative review.宫颈癌:挑战与预防策略:一篇叙述性综述
Health Sci Rep. 2024 May 30;7(6):e2149. doi: 10.1002/hsr2.2149. eCollection 2024 Jun.
2
Reviewing FIGO 2018 cervical cancer staging.回顾国际妇产科联盟(FIGO)2018年宫颈癌分期。
Acta Obstet Gynecol Scand. 2023 Dec;102(12):1757-1758. doi: 10.1111/aogs.14667. Epub 2023 Aug 17.
3
Critical analysis of the FIGO 2018 cervical cancer staging.对国际妇产科联盟(FIGO)2018年宫颈癌分期的批判性分析。
J Turk Ger Gynecol Assoc. 2022 Dec 8;23(4):325-326. doi: 10.4274/jtgga.galenos.2022.2022-1-10. Epub 2022 Jul 5.
4
Nomogram Predicting Overall Survival in Patients with FIGO II to III Squamous Cell Cervical Carcinoma Under Radical Radiotherapy: A Retrospective Analysis Based on 2018 FIGO Staging.基于2018年国际妇产科联盟(FIGO)分期的诺模图预测接受根治性放疗的FIGO II至III期宫颈鳞状细胞癌患者的总生存期:一项回顾性分析
Cancer Manag Res. 2021 Dec 29;13:9391-9400. doi: 10.2147/CMAR.S336892. eCollection 2021.
5
The effect of dose-painted intensity-modulated radiotherapy combined with chemotherapy for stage IIIB cervical cancer.剂量勾画调强放疗联合化疗治疗IIIB期宫颈癌的疗效
Am J Transl Res. 2021 Apr 15;13(4):2813-2821. eCollection 2021.
6
Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam.越南采用根治性同期放化疗治疗 2018 年 FIGO 分期 III 期宫颈癌患者的治疗结果和预后因素。
Asian Pac J Cancer Prev. 2021 Mar 1;22(3):853-859. doi: 10.31557/APJCP.2021.22.3.853.
7
Escalated radiation and prophylactic extended field nodal irradiation are beneficial for FIGO IIIB cervical cancer patients' prognosis.对于 FIGO IIIB 期宫颈癌患者,采用升级放疗和预防性扩大野淋巴结照射可改善预后。
Radiat Oncol. 2018 Nov 20;13(1):223. doi: 10.1186/s13014-018-1172-1.

本文引用的文献

1
Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.基于NRG肿瘤学/妇科肿瘤学组同步放化疗随机试验中患者可识别的预后因素分析开发的列线图,用于预测局部晚期宫颈癌的无进展生存期、总生存期和盆腔复发。
J Clin Oncol. 2015 Jul 1;33(19):2136-42. doi: 10.1200/JCO.2014.57.7122. Epub 2015 Mar 2.
2
Long-term outcomes of concomitant chemoradiotherapy incorporating high-dose-rate brachytherapy to treat locally advanced cervical cancer.采用高剂量率近距离放疗的同步放化疗治疗局部晚期宫颈癌的长期疗效
Tumori. 2012 Sep-Oct;98(5):615-21. doi: 10.1177/030089161209800512.
3
Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer.比较局部晚期宫颈癌中鳞癌和腺癌的治疗效果。
Gynecol Oncol. 2012 May;125(2):292-6. doi: 10.1016/j.ygyno.2012.01.034. Epub 2012 Jan 28.
4
Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer.基于协议的影像(MRI)引导自适应近距离放疗联合或不联合化疗治疗局部晚期宫颈癌的临床结果。
Radiother Oncol. 2011 Jul;100(1):116-23. doi: 10.1016/j.radonc.2011.07.012. Epub 2011 Aug 5.
5
Hydronephrosis as a prognostic indicator of survival in advanced cervix cancer.积水肾作为晚期宫颈癌生存预后的一个指标。
Int J Gynecol Cancer. 2011 Aug;21(6):1091-6. doi: 10.1097/IGC.0b013e31821cabc8.
6
Reporting and validation of gynaecological Groupe Euopeen de Curietherapie European Society for Therapeutic Radiology and Oncology (ESTRO) brachytherapy recommendations for MR image-based dose volume parameters and clinical outcome with high dose-rate brachytherapy in cervical cancers: a single-institution initial experience.报告和验证妇科欧洲放射治疗和肿瘤学学会(ESTRO)近距离放射治疗建议的基于磁共振成像的剂量体积参数和宫颈癌高剂量率近距离放射治疗的临床结果:单机构初步经验。
Int J Gynecol Cancer. 2011 Aug;21(6):1110-6. doi: 10.1097/IGC.0b013e31821caa55.
7
Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study.积水对盆腔内疾病局限的 IIIB 期宫颈癌患者接受放疗和同期化疗的预后影响:一项妇科肿瘤学组的研究。
Gynecol Oncol. 2010 May;117(2):270-5. doi: 10.1016/j.ygyno.2010.01.045. Epub 2010 Feb 24.
8
Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.国际妇产科联盟(FIGO)对外阴癌、宫颈癌和子宫内膜癌分期的修订版。
Int J Gynaecol Obstet. 2009 May;105(2):103-4. doi: 10.1016/j.ijgo.2009.02.012.
9
High-dose-rate intracavitary irradiation using linear source arrangement for stage II and III squamous cell carcinoma of the uterine cervix.采用线性源排列的高剂量率腔内照射治疗II期和III期子宫颈鳞状细胞癌。
Radiother Oncol. 1998 May;47(2):207-13. doi: 10.1016/s0167-8140(97)00229-6.
10
The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy.放射治疗的子宫颈鳞状细胞癌患者治疗前和治疗后鳞状细胞癌抗原(SCC)水平的预后意义
Int J Radiat Oncol Biol Phys. 1998 Jul 1;41(4):823-30. doi: 10.1016/s0360-3016(98)00147-3.

比较有和没有阴道下三分之一受累的IIIB期宫颈癌患者的治疗结果。

Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion.

作者信息

Katanyoo Kanyarat

机构信息

Radiation Oncology Unit, Department of Radiology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.

出版信息

J Gynecol Oncol. 2017 Nov;28(6):e79. doi: 10.3802/jgo.2017.28.e79.

DOI:10.3802/jgo.2017.28.e79
PMID:29027397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5641529/
Abstract

OBJECTIVE

To evaluate treatment outcomes between stage IIIB cervical cancer with and without lower third of vaginal invasion (LTI) in terms of response to treatment and overall survival (OS).

METHODS

Matching one patient with LTI for 2 patients without LTI who had completed treatment between 1995 and 2012 were conducted by using treatment modalities (radiation therapy [RT] alone vs. concurrent chemoradiation therapy [CCRT]) and tumor histology (squamous cell carcinoma [SCC] vs. adenocarcinoma [ADC]). Treatment outcomes including complete response (CR) rate of RT/CCRT, patterns of treatment failure and survival outcomes were analyzed.

RESULTS

Of 216 stage IIIB cervical cancer patients, 114 of them had no LTI and 72 had LTI. Most of the patients (83.8%) had tumor histology as SCC. The CR rates between stage IIIB without LTI and with LTI were 93.8% and 81.9% (p=0.009), and corresponding with disease progression at pelvis accounted for 18.2% and 34.4% (p=0.017), respectively. Distant metastasis was comparable between 2 groups of patients, 28.9% in patients without LTI and 29.5% in patients with LTI (p=0.988). The 2-year and 5-year OS of stage IIIB without LTI were 66.5% and 46.8% compared to stage IIIB with LTI which were 43.1% and 28.9% (p=0.004), respectively. For multivariable analysis, stage IIIB with LTI was only the influential factor on OS with hazard ratio (HR) of 1.63 (p=0.012).

CONCLUSION

Stage IIIB cervical cancer patients with LTI have poorer treatment outcomes including response to treatment and survival outcomes than patients in the same stage without LTI.

摘要

目的

从治疗反应和总生存期(OS)方面评估有和无阴道下三分之一浸润(LTI)的IIIB期宫颈癌的治疗结果。

方法

通过使用治疗方式(单纯放疗[RT]与同步放化疗[CCRT])和肿瘤组织学类型(鳞状细胞癌[SCC]与腺癌[ADC]),对1995年至2012年间完成治疗的1例有LTI的患者与2例无LTI的患者进行匹配。分析治疗结果,包括RT/CCRT的完全缓解(CR)率、治疗失败模式和生存结果。

结果

在216例IIIB期宫颈癌患者中,114例无LTI,72例有LTI。大多数患者(83.8%)的肿瘤组织学类型为SCC。无LTI和有LTI的IIIB期患者的CR率分别为93.8%和81.9%(p = 0.009),盆腔疾病进展分别占18.2%和34.4%(p = 0.017)。两组患者的远处转移情况相当,无LTI患者为28.9%,有LTI患者为29.5%(p = 0.988)。无LTI的IIIB期患者的2年和5年总生存率分别为66.5%和46.8%,而有LTI的IIIB期患者分别为43.1%和28.9%(p = 0.004)。多变量分析显示,有LTI的IIIB期是影响总生存期的唯一因素,风险比(HR)为1.63(p = 0.012)。

结论

与同阶段无LTI的患者相比,有LTI的IIIB期宫颈癌患者的治疗结果,包括治疗反应和生存结果更差。